- Question
- Does immediate VA-ECMO improve clinical outcomes compared with an initially conservative strategy in patients with rapidly deteriorating or severe cardiogenic shock?
- Design
- Multicenter, randomized, investigator-initiated academic clinical trial with 122 patients randomized. Five were excluded for lack of informed consent, leaving 117 analyzed (58 and 59 per group).
- Population
- Patients with rapidly deteriorating or severe cardiogenic shock.
- Intervention
- Immediate implementation of veno-arterial ECMO, with other diagnostic and therapeutic procedures per standard of care.
- Control
- Initial conservative therapy per usual practice, allowing downstream use of VA-ECMO if hemodynamic status worsened.
- Primary outcome
- Composite of all-cause death, resuscitated circulatory arrest, and implementation of another mechanical circulatory support device at 30 days.
- Results
- The primary endpoint occurred in 37 patients (63.8%) with immediate VA-ECMO and 42 (71.2%) with the conservative strategy (HR 0.72; 95% CI 0.46-1.12; P=0.21). VA-ECMO was used downstream in 23 (39%) of the conservative group. All-cause mortality at 30 days was 50.0% vs 47.5%.
- Safety
- Serious adverse events were similar (60.3% vs 61.0%), with no statistically significant differences in sepsis, pneumonia, stroke, leg ischemia or bleeding.
- Conclusion
- Immediate VA-ECMO did not improve clinical outcomes compared with an early conservative strategy that allowed downstream VA-ECMO if hemodynamics worsened.
- Why it matters
- It challenged routine immediate use of VA-ECMO in cardiogenic shock and added randomized evidence in an area where it was scarce; it suggests reserving support for patients who deteriorate.
Card generated automatically with AI from the abstract of the original publication and the trial registry; every figure was checked against those sources. It may contain errors: verify the data at the source before using it for clinical decisions.
Generated on October 14, 2026